ROBINS CHAD M 4

What Happened

• Chad M. Robins, CEO, Chairman and a director of Adaptive Biotechnologies (ADPT), sold 124,998 shares in an open-market transaction on February 2, 2026. The reported weighted-average price was $18.44 per share, producing aggregate proceeds of about $2,304,963. This was a sale (code S), which is often routine; the transaction was executed pursuant to a pre-established plan.

Key Details

• Transaction date: 2026-02-02; Form 4 filed: 2026-02-04 (timely within the 2-business-day reporting window).
• Amount sold: 124,998 shares; weighted-average price reported: $18.44; total proceeds: ~$2,304,963.
• Price range: shares were sold in multiple trades at prices between $18.16 and $18.88 (footnote F2).
• Plan/authorization: Transactions were effected under a Rule 10b5-1 trading plan adopted August 11, 2025 (footnote F1).
• Shares owned after the transaction: not specified in the excerpt provided.
• Filing status: timely (not reported as late).

Context

• A 10b5-1 plan indicates the sales were pre-planned and authorized in advance, which can mean the trade was automatic and not necessarily a signal of the insider’s current view. For retail investors, purchases tend to be more informative about insider conviction than routine pre-planned sales. If you want the per-trade price breakdown, the filer offers to provide detailed information on request per footnote F2.